heart
base
tumor
hbt
lie
near
coronari
arteri
ca
circul
potenti
recruit
coronari
flow
result
steal
phenomenon
stereotact
radiat
therapi
srt
use
treat
hbt
peopl
caus
detriment
effect
ca
includ
endotheli
dysfunct
acceler
arteriosclerosi
aim
retrospect
studi
evalu
ca
proxim
hbt
comput
tomographi
angiographi
cta
quantifi
radiat
dose
ca
dog
treat
srt
dog
underw
cta
hbt
epicardi
ca
categor
within
adjac
distant
hbt
dog
underw
srt
ca
contour
quantifi
radiat
dose
receiv
left
vs
right
ca
system
direct
recruit
ca
flow
hbt
seen
case
deriv
circumflex
ca
dog
left
ca
right
ca
least
one
ca
within
hbt
case
adjac
case
ca
distant
hbt
dog
higher
radiat
dose
receiv
left
ca
system
dog
whose
left
ca
branch
within
touch
hbt
p
similar
trend
seen
right
ca
p
dog
hbt
commonli
lie
proxim
epicardi
ca
recruit
flow
ca
srt
hbt
expos
ca
radiat
taken
togeth
coronari
steal
radiat
damag
may
caus
risk
myocardi
ischemia
dog
hbt
benefit
pimobendan
treatment
felin
hypertroph
cardiomyopathi
hcm
demonstr
random
control
clinic
trial
object
exploratori
studi
investig
effect
pimobendan
cat
hcm
recent
congest
heart
failur
chf
without
left
ventricular
outflow
tract
obstruct
lvoto
aim
search
possibl
endpoint
larger
pivot
studi
prospect
random
global
studi
cat
hcm
recent
resolv
chf
within
last
day
random
cat
cat
without
lvoto
cat
receiv
either
pimobendan
mgkg
n
placebo
n
conjunct
furosemid
proport
cat
reach
primari
endpoint
n
pimobendan
placebo
full
analysi
set
popul
n
differ
treatment
group
p
cat
without
lvoto
n
numer
higher
success
rate
pimobendan
n
compar
placebo
n
odd
ratio
ci
wherea
cat
lvoto
n
numer
higher
success
rate
placebo
n
compar
pimobendan
n
odd
ratio
ci
incid
advers
event
compar
treatment
group
p
pimobendan
administr
lead
improv
outcom
studi
addit
endpoint
pivot
studi
identifi
autoimmun
associ
autoantibodi
direct
receptor
increasingli
accept
drive
human
idiopath
dilat
cardiomyopathi
idcm
new
neutral
pathogen
autoantibodi
aptam
bc
show
promis
result
vitro
vivo
hypertens
rat
object
studi
determin
safeti
efficaci
treatment
aptam
bc
doberman
pinscher
spontan
dcm
evalu
efficaci
aptam
bc
doberman
pinscher
occult
phase
docm
dog
got
infus
aptam
bc
compar
doberman
pinscher
receiv
background
treatment
pimobendan
antiarrhythm
drug
aptam
bc
infus
dog
develop
congest
heart
failur
chf
cours
studi
receiv
furosemid
addit
primari
endpoint
defin
death
cardiac
reason
advers
event
occur
infus
aptam
bc
indic
administr
safe
use
dog
estim
median
time
primari
endpoint
significantli
longer
dog
receiv
aptam
day
iqr
day
dog
dcm
control
group
day
iqr
day
log
rank
p
given
pilot
studi
small
studi
popul
remain
necessari
valid
find
random
studi
left
heart
failur
common
dog
advanc
myxomat
mitral
valv
degener
mmvd
frequent
fatal
refractori
medic
manag
side
effect
therapi
manifest
left
atrial
decompress
lad
involv
creat
iatrogen
atrial
septal
defect
iasd
via
percutan
jugular
catheter
rapidli
reduc
left
atrial
hypertens
case
record
one
author
ja
retrospect
review
dog
advanc
mmvd
chronic
left
chf
underw
left
atrial
decompress
six
dog
identifi
hospit
congest
heart
failur
chf
time
lad
azotem
time
lad
lad
surviv
patient
success
reduc
left
atrial
pressur
greater
patient
one
patient
final
lap
unabl
measur
technic
reason
size
final
balloon
dilat
across
atrial
septum
mm
first
dog
mm
mm
procedur
time
minut
complic
procedur
includ
pericardi
effus
arrhythmia
atrial
prematur
complex
atrial
flutter
arrhythmia
either
resolv
therapi
dog
three
dog
discharg
follow
day
discharg
day
die
within
hour
procedur
euthanasia
respiratori
failur
sign
left
chf
resolv
surviv
dog
follow
procedur
reduct
diuret
dose
achiev
patient
evid
worsen
pulmonari
hypertens
right
chf
evid
patient
month
one
dog
requir
increas
diuret
dose
day
iasd
note
smaller
initi
creat
mm
vs
mm
day
suggest
spontan
closur
respons
chf
dog
develop
recrudesc
pulmonari
edema
day
time
defect
patent
procedur
success
repeat
discharg
follow
day
remain
surviv
dog
free
congest
sign
patent
iasd
time
report
submiss
left
atrial
decompress
result
rapid
reduct
left
atrial
pressur
may
promis
therapeut
option
dog
current
medic
therapi
limit
investig
necessari
determin
appropri
time
patient
select
size
iasd
optim
outcom
diagnosi
c
difficil
infect
cdi
involv
multipl
approach
fecal
sampl
test
includ
detect
organ
via
antigen
glutamad
dehydrogenas
elisa
cultur
detect
toxin
gene
pcr
detect
toxin
via
elisa
discord
antigen
toxin
elisa
result
may
encount
hors
complic
diagnosi
object
studi
evalu
abil
isol
toxigen
c
difficil
antigen
posit
toxin
neg
sampl
fecal
sampl
collect
foal
rang
day
week
age
present
referr
hospit
diarrhea
andor
enter
develop
diarrhea
enter
hospit
sampl
perform
inclus
part
routin
diagnost
test
fecal
sampl
test
c
difficil
use
elisa
detect
c
difficil
antigen
glutam
dehydrogenas
toxin
b
c
diff
quik
chek
complet
techlab
blacksburg
va
usa
studi
period
fecal
sampl
test
c
difficil
yield
antigen
posit
toxin
neg
result
sampl
antigen
posit
toxin
neg
evalu
enrich
cultur
clostridium
difficil
isol
antigen
posit
toxin
neg
sampl
recov
isol
toxigen
possess
gene
encod
toxin
b
clinic
relev
antigen
posit
toxin
neg
result
need
studi
foal
studi
enter
could
consist
cdi
potenti
caus
diseas
identifi
blood
concentr
higher
poni
gastrointestin
diseas
hors
possibl
due
differ
bodi
condit
bc
therefor
correl
concentr
measur
bc
investig
healthi
hors
poni
poni
influenc
endocrin
statu
concentr
also
investig
blood
sampl
obtain
poni
hors
breed
weight
height
measur
bc
concentr
record
poni
triglycerid
acth
concentr
measur
oral
glucos
test
perform
correl
bc
paramet
establish
associ
concentr
equid
type
poni
hors
bc
age
glucos
concentr
investig
multivari
model
weak
p
neg
correl
detect
concentr
averag
bc
score
r
heart
girth
height
ratio
r
age
r
glucos
concentr
weakli
correl
r
p
poni
weak
neg
correl
triglycerid
concentr
detect
r
p
signific
correl
endocrin
paramet
multivari
model
age
p
heart
girth
height
ratio
p
significantli
associ
repres
reduct
per
year
increas
age
reduct
per
unit
increas
heart
girth
height
ratio
age
bc
influenc
blood
concentr
significantli
weakli
clinic
sign
idiopath
hypocalcemia
thoroughbr
tb
foal
includ
hypocalcem
tetani
recumb
variabl
activ
condit
invari
fatal
base
sever
clinic
phenotyp
occurr
tb
breed
similar
inherit
infantil
hypocalcemia
human
genet
investig
perform
clinicopatholog
data
two
affect
tb
foal
exclud
caus
hypocalcemia
pedigre
analysi
reveal
like
autosom
recess
mode
inherit
foal
relat
sire
side
within
gener
dam
side
within
gener
dna
sampl
foal
dam
sequenc
coverag
illumina
sequenc
read
trim
map
variant
identifi
initi
candid
gene
implic
human
inherit
hypocalcemia
casr
evalu
put
genet
mutat
none
identifi
investig
potenti
variant
associ
studi
perform
segreg
put
function
variant
result
homozyg
nonsens
mutat
gene
encod
guanin
nucleotid
exchang
factor
highli
associ
idiopath
hypocalcemia
alter
base
pair
conserv
across
vertebra
speci
addit
genet
variant
identifi
hors
breed
compar
data
reveal
express
ubiquit
protein
level
transcript
predominantli
express
parathyroid
tissu
therefor
nonsens
mutat
guanin
nucleotid
exchang
factor
like
caus
variant
idiopath
hypocalcemia
thoroughbr
foal
fourth
intern
havemey
workshop
equid
herpesvirus
ehv
held
beaufort
north
carolina
octob
attend
scientist
contin
major
focu
workshop
addit
present
gamma
herpesvirus
program
address
sever
critic
area
epidemiolog
manag
genet
divers
studi
australia
demonstr
limit
recombin
compar
prevent
outbreak
intervent
studi
continu
demonstr
import
rapid
diagnosi
abil
ehv
spread
amongst
differ
wildlif
speci
environ
primarili
water
hole
investig
africa
mongolia
pathogenesi
impact
infect
earli
pregnanc
loss
mesenchym
stem
cell
report
togeth
immun
respons
nasopharynx
blood
cerebrospin
fluid
follow
experiment
infect
infect
also
show
induc
procoagul
state
endotheli
cell
transport
endotheli
pathogenesi
site
mononuclear
cell
spread
demonstr
use
new
flow
chamber
model
diagnost
virolog
role
immun
biomark
nasopharynx
sera
experiment
infect
studi
view
identifi
immun
protect
anim
could
releas
quarantin
lamp
assay
differenti
vs
neuropathogen
vs
biotyp
infect
develop
infect
model
sever
vitro
model
describ
studi
interact
respiratori
epithelium
endotheli
cell
pbmc
reveal
potenti
novel
strategi
futur
therapeut
intervent
vivo
impact
infect
sever
month
infect
reveal
histolog
chang
sever
organ
includ
nervou
system
test
eye
immun
therapi
import
intranas
immun
primarili
mediat
igg
isotyp
describ
impact
gd
gene
delet
vs
infect
pathogenesi
report
sever
studi
explor
develop
cellular
immun
role
peptid
motif
cytotox
specif
virus
thought
global
distribut
import
rare
sporad
diseas
equin
multinodular
pulmonari
fibrosi
respiratori
reproduct
diseas
remain
uncertain
new
pcr
diagnost
test
vitromodel
epidemiolog
studi
describ
includ
impact
age
distribut
respiratori
diseas
gastric
mucosa
manag
salmonella
enterica
hors
typic
focus
clinic
affect
anim
howev
subclin
shed
like
much
common
greatli
exacerb
environment
contamin
potenti
increas
transmiss
risk
among
stablem
hospit
hors
typic
discharg
within
day
admiss
subsequ
detect
shed
increas
concern
regard
transmiss
prevent
home
set
order
make
recommend
regard
manag
individu
hors
popul
must
understand
durat
shed
among
affect
hors
vital
part
epidemiolog
salmonella
equin
popul
end
object
studi
character
durat
salmonella
shed
among
hors
describ
factor
associ
shed
durat
investig
advers
effect
creat
exposur
hors
stablem
subclin
clinic
affect
hors
cultur
weekli
week
isol
phenotyp
character
survey
conduct
determin
factor
associ
shed
impact
stablem
gener
hors
clinic
salmonellosi
like
intermitt
shed
enterica
fece
greater
median
durat
pair
tend
parallel
shed
pattern
irrespect
clinic
subclin
shed
result
studi
indic
hors
clinic
salmonellosi
like
pose
greater
risk
environment
contamin
subclin
affect
hors
may
contribut
ongo
transmiss
precaut
taken
irrespect
diseas
statu
aortopulmonari
fistul
apf
extrem
rare
gener
hors
popul
rel
common
friesian
hors
typic
transvers
tear
aorta
occur
near
remnant
ligamentum
arteriosum
format
fistula
toward
pulmonari
arteri
fistul
often
rel
long
irregular
shape
tract
wide
rang
clinic
sign
may
occur
tachycardia
right
heart
failur
pulmonari
hypertens
usual
present
often
holosystol
earli
diastol
murmur
found
dorsal
aortic
valv
area
obtain
good
qualiti
cardiac
ultrasound
imag
may
challeng
friesian
due
bodi
conform
purpos
studi
describ
take
diagnost
ultrasound
imag
apf
applic
equin
practic
data
friesian
geld
mare
mean
bodi
weight
kg
includ
age
rang
year
median
hors
underw
full
echocardiograph
exam
includ
color
flow
doppler
addit
specif
view
acquir
visual
apf
hors
show
ultrasound
chang
compat
sever
pulmonari
hypertens
decreas
aortic
size
right
parastern
left
ventricular
outflow
tract
view
right
ventricular
rv
view
figur
apf
could
visual
triangl
right
atrium
ra
aorta
ao
pulmonari
arteri
pa
hors
lesion
sometim
subtl
color
flow
examin
view
show
abnorm
flow
suggest
apf
hors
one
hors
show
aortic
dissect
circular
cuff
entir
visibl
aorta
view
pa
third
intercost
space
superior
visual
apf
cranial
slight
dorsal
angul
rotat
figur
pa
ao
visual
subsequ
cours
pa
follow
bifurc
gradual
rotat
probe
clockwis
simultan
angl
dorsal
caudal
view
apf
could
clearli
identifi
pa
ao
hors
locat
dorsal
pa
caudal
ventral
ao
color
flow
doppler
indic
turbul
flow
apf
pa
hors
actual
tear
vessel
could
identifi
hors
hors
apf
confirm
conclus
friesian
apf
show
ultrasound
find
indic
pulmonari
hypertens
right
heart
failur
howev
accur
diagnosi
specif
ultrasound
view
aorta
pulmonari
arteri
need
longitudin
imag
pa
taken
left
third
intercost
space
clearli
show
apf
hors
studi
perform
investig
whether
week
treatment
inject
omeprazol
io
bova
uk
effect
treatment
week
licens
buffer
omeprazol
past
oo
administ
po
sid
treat
equin
squamou
glandular
gastric
diseas
retrospect
review
clinic
case
perform
hors
age
year
repres
wide
rang
breed
disciplin
gastroscopi
perform
prior
treatment
week
treatment
gastroscop
examin
perform
week
io
hors
anonymis
gastroscopi
imag
review
blind
detail
treatment
statist
perform
compar
two
treatment
signific
differ
group
hors
eggd
met
inclus
criteria
receiv
io
receiv
oo
lesion
within
pylor
antrum
differ
sever
group
hors
esgd
met
inclus
criteria
receiv
io
receiv
oo
differ
squamou
lesion
distribut
grade
two
treatment
group
treatment
failur
rate
eggd
esgd
present
tabl
inject
omeprazol
found
oral
omeprazol
heal
improv
glandular
p
squamou
lesion
p
io
group
signific
improv
compar
eggd
esgd
lesion
within
week
given
larg
differ
failur
rate
two
treatment
investig
larger
number
justifi
determin
whether
io
superior
oo
stress
result
cortisol
concentr
elev
howev
critic
ill
relat
corticosteroid
insuffici
circi
cortisol
concentr
adren
respons
acth
stimul
inadequ
clinic
featur
consequ
circi
describ
adult
hors
medic
record
hors
admit
emerg
stimul
synthet
acth
perform
review
circi
defin
baselin
cortisol
cortisol
delta
cortisol
variabl
associ
circi
surviv
system
inflammatori
respons
syndrom
sir
presenc
ischem
lesion
investig
p
consid
signific
hors
includ
circi
admiss
addit
develop
circi
hospit
die
sir
ischem
lesion
admiss
hors
circi
higher
acth
concentr
lower
cortisol
delta
cortisol
insulin
concentr
less
like
surviv
p
survivor
lower
acth
cortisol
concentr
admiss
day
higher
cortisol
admiss
day
less
like
circi
ischaem
lesion
reflux
p
hors
sir
higher
glucos
concentr
p
hors
ischaem
lesion
higher
acth
cortisol
glucos
concentr
admiss
lower
insulin
concentr
day
like
sir
surviv
p
multivari
analysi
could
fit
outcom
circi
adult
hors
common
character
high
acth
low
cortisol
low
delta
cortisol
associ
zika
viru
zikv
member
flavivirda
famili
emerg
pathogen
human
gestat
zikv
induc
placent
inflamm
insuffici
limit
effect
nutrient
exchang
directli
damag
fetal
tissu
increas
spread
viru
along
lack
knowledg
mechan
viral
pathogenesi
demonstr
need
develop
appropri
anim
model
pathogenesi
investig
main
object
studi
develop
relev
model
studi
viral
dynam
interfac
includ
fetal
congenit
abnorm
use
sheep
research
hypothesi
pregnant
sheep
inocul
zikv
would
permiss
viral
replic
result
transmiss
develop
fetu
order
critic
test
hypothesi
pregnant
ewe
carri
fetu
enrol
studi
randomli
distribut
treatment
group
receiv
ia
n
intravascular
iv
n
intravagin
va
n
inocul
ffu
zikv
strain
clinic
ill
score
assess
daili
blood
collect
daili
day
post
inocul
dpi
pcr
perform
identifi
viremia
dam
transabdomin
ultrasound
perform
weekli
assess
fetal
viabil
clinic
ill
observ
sheep
follow
inocul
follow
dpi
dpi
fetal
wastag
occur
sheep
ia
iv
group
respect
molecular
techniqu
perform
confirm
zikv
studi
demonstr
feasibl
anim
model
investig
aspect
zikv
infect
includ
spread
placent
cell
tropism
signific
interest
understand
respiratori
microbiom
specif
certain
phenotyp
may
relat
diseas
suscept
dairi
calv
potenti
relev
data
includ
improv
screen
diagnost
develop
respiratori
probiot
mani
survey
studi
perform
first
studi
author
knowledg
investig
short
term
effect
experiment
bacteri
challeng
upper
lower
respiratori
tract
microbiota
purpos
primari
object
studi
evalu
whether
bacteri
composit
divers
characterist
nasopharyng
np
microbiota
protect
pneumonia
follow
experiment
challeng
pasteurella
multocida
secondari
object
studi
evalu
effect
bacteri
challeng
ampicillin
therapi
np
tonsillar
tracheobronchi
lymph
node
lung
microbiota
dairi
calv
conveni
sampl
healthi
holstein
bull
calv
mean
age
day
enrol
juli
hous
laboratori
experiment
protocol
approv
institut
anim
care
use
committe
day
acclim
calv
examin
clinic
respiratori
score
rs
lung
ultrasound
score
uss
calv
normal
rs
uss
select
bacteri
challeng
day
challeng
deep
np
swab
collect
next
day
calv
sedat
video
laryngoscop
use
pass
cathet
distal
trachea
ml
cfuml
p
multocida
administ
calv
monitor
interv
rs
uss
uss
show
signific
consolid
second
deep
np
swab
collect
calv
random
receiv
either
ampicillin
trihydr
n
label
dose
x
day
equal
volum
durat
steril
salin
n
two
calv
develop
signific
lung
consolid
follow
bacteri
challeng
includ
treatment
random
calv
monitor
daili
via
rs
uss
day
day
third
deep
np
swab
collect
calv
sedat
euthan
postmortem
sampl
np
tonsil
lung
tracheobronchi
lymph
node
collect
np
swab
tissu
sampl
store
process
simultan
follow
dna
extract
swab
cm
section
tissu
region
rrna
gene
amplifi
use
pcr
librari
sequenc
use
illumina
miseq
platform
sequenc
cluster
oper
taxonom
unit
use
mothur
taxonomi
divers
data
analyz
rstudio
alpha
divers
compar
use
anova
wilcoxon
rank
sum
test
beta
divers
compar
use
permanova
test
linear
regress
model
fit
evalu
effect
np
divers
characterist
health
outcom
mix
linear
regress
model
fit
calf
random
effect
evalu
effect
sampl
type
ampicillin
treatment
divers
metric
microbiota
rel
abund
ra
bacteri
genera
compar
use
kruskal
walli
test
calv
higher
np
alpha
divers
rs
posit
less
day
p
follow
bacteri
challeng
control
serum
total
protein
day
age
ampicillin
treatment
trial
np
alpha
divers
associ
uss
p
signific
differ
alpha
divers
among
np
swab
collect
p
alpha
divers
differ
third
np
swab
postmortem
tissu
sampl
p
alpha
divers
third
np
swab
postmortem
tissu
sampl
affect
ampicillin
treatment
p
bacteri
challeng
p
beta
divers
differ
three
np
swab
p
third
np
swab
tissu
sampl
p
prior
challeng
top
np
genera
bacteroid
sp
mycoplasma
sp
escherichia
sp
prevotella
sp
unclassifi
microbacteriacea
sp
follow
bacteri
challeng
top
genera
includ
prevotella
sp
pasteurella
sp
mycoplasma
sp
acinetobact
sp
unclassifi
microbacteriacea
sp
third
np
swab
postmortem
tissu
sampl
second
third
np
swab
higher
ra
pasteurella
sp
compar
np
swab
p
first
np
swab
higher
ra
escherichia
sp
compar
np
swab
p
ra
mycoplasma
sp
first
np
swab
higher
calv
develop
lung
lesion
faster
follow
challeng
p
ra
sharpea
sp
first
np
swab
higher
calv
took
longer
develop
lung
lesion
challeng
p
ra
pasteurella
sp
third
swab
tissu
sampl
affect
antibiot
therapi
p
ra
pasteurella
sp
differ
swab
tissu
sampl
p
tonsil
sampl
lowest
ra
pasteurella
sp
highest
ra
acinetobact
sp
compar
swab
tissu
sampl
p
conclus
increas
np
alpha
divers
protect
clinic
respiratori
diseas
challeng
calv
studi
increas
ra
mycoplasma
sp
associ
rapid
develop
lung
lesion
increas
ra
sharpea
sp
associ
slower
develop
lung
lesion
follow
bacteri
challeng
interestingli
ra
pasteurella
sp
affect
antibiot
treatment
np
swab
postmortem
tissu
sampl
increas
speed
lung
lesion
develop
calv
higher
ra
mycoplasma
sp
may
relat
synergi
challeng
strain
resid
strain
mycoplasma
sp
within
np
sharpea
sp
lactic
acid
bacteria
potenti
antagonist
activ
gram
neg
infect
bacteri
popul
may
partial
inhibit
growth
challeng
strain
resist
mdr
emerg
issu
mannheimia
haemolytica
varieti
suscept
test
method
avail
clinic
use
object
studi
compar
result
disk
diffus
broth
microdilut
whole
genom
sequenc
wg
suscept
test
haemolytica
isol
collect
mass
medic
tulathromycin
isol
subject
antimicrobi
suscept
test
disk
diffus
broth
microdilut
whole
genom
sequenc
given
antimicrobi
percentag
isol
classifi
suscept
intermedi
resist
compar
three
method
use
exact
test
margin
homogen
overal
categor
agreement
test
method
rang
lowest
agreement
comparison
broth
microdilut
wg
penicillin
cattl
prior
mass
medic
perfect
agreement
found
ceftiofur
enrofloxacin
florfenicol
oxytetracyclin
gamithromycin
test
method
isol
prior
mass
medic
ceftiofur
enrofloxacin
oxytetracyclin
gamithromycin
tilmicosin
test
method
mass
medic
major
error
fals
suscept
detect
possibl
comparison
prior
mass
medic
comparison
mass
medic
major
error
fals
resist
minor
error
error
detect
comparison
prior
mass
medic
comparison
mass
medic
respect
result
studi
show
discrep
result
differ
suscept
test
method
exist
suggest
need
harmon
suscept
test
method
pharmacokinet
studi
drug
milk
often
limit
due
infrequ
sampl
associ
milk
altern
frequent
sampl
collect
repeat
milk
may
increas
drug
elimin
previou
work
intraven
administ
flunixin
demonstr
continu
sampl
udder
use
ultrafiltr
effect
mean
address
concern
object
studi
continu
sampl
healthi
mastit
quarter
cow
natur
occur
mastiti
compar
drug
concentr
intramammari
infus
ceftiofur
ultrafiltr
probe
place
ultrasound
guidanc
gland
cistern
normal
mastit
quarter
ten
matur
cow
holstein
jersey
cow
natur
occur
subclin
mastiti
ultrafiltr
probe
secur
caudal
later
aspect
udder
depend
quarter
sampl
ceftiofur
hydrochlorid
mg
spectramast
lc
infus
sampl
quarter
time
hour
ultrafiltr
sampl
collect
hour
post
initi
drug
administr
cow
routin
milk
machin
everi
hour
milk
weight
collect
aliquot
milk
collect
treat
quarter
immedi
prior
milk
milk
conclus
milk
equal
volum
aliquot
mix
assess
drug
concentr
whole
milk
ceftiofur
metabolit
analyz
liquid
chromatographi
tandem
mass
spectrometri
uplcmsm
milk
sampl
asept
collect
treat
quarter
immedi
prior
treatment
day
treatment
aerob
cultur
sampl
obtain
healthi
quarter
infect
quarter
infect
quarter
posit
staphylococcu
spp
cn
posit
aureu
posit
streptococcu
uberi
aerococcu
spp
escherichia
coli
six
mastit
quarter
cultur
neg
conclus
studi
one
cn
one
aureu
infect
elimin
healthi
quarter
remain
neg
throughout
studi
conclus
ongo
drug
analysi
determin
impact
mastiti
activ
ceftiofur
concentr
udder
correl
pharmacokinet
paramet
treatment
outcom
conclud
collect
ultrafiltr
sampl
mammari
gland
cow
provid
viabl
mean
continu
assess
drug
concentr
milk
continu
milk
cow
normal
accur
associ
pharmacokinet
paramet
treatment
outcom
canin
degen
myelopathi
dm
share
similar
superoxid
dismutas
human
amyotroph
later
sclerosi
al
brain
microstructur
patholog
quantifi
use
diffus
tensor
imag
dti
al
patient
object
use
dti
character
neurodegen
chang
brain
dm
dog
longitudin
determin
relationship
clinic
sever
brain
dti
perform
baselin
everi
month
fraction
anisotropi
fa
mean
diffus
md
axial
diffus
ad
radial
diffus
rd
calcul
region
interest
specif
white
grey
matter
area
gait
score
normal
tetraplegia
assign
time
scan
dti
valu
compar
gait
score
evalu
time
use
pearson
correl
univari
approach
respect
sixteen
dm
dog
includ
mean
age
year
mean
time
onset
sign
first
mri
month
mean
baselin
gait
score
mean
score
chang
baselin
last
scan
scan
includ
dog
scan
dti
valu
poorli
correl
gait
score
comparison
among
dog
scan
fa
intern
capsul
decreas
time
p
dti
detect
longitudin
chang
brain
dm
dog
show
consist
relationship
diseas
sever
studi
warrant
larger
cohort
dog
clarifi
relationship
brain
dti
valu
progress
dm
studi
aim
evalu
analges
effect
gabapentin
alon
g
combin
meloxicam
gm
dog
neuropath
pain
pain
dog
includ
prospect
random
clinic
trial
physic
neurolog
examin
lesion
confirm
via
mri
dog
alloc
receiv
gplacebogm
gmplacebog
day
daystreat
includ
rest
client
measur
csom
canin
brief
pain
inventori
cbpi
pain
function
overal
impress
dynam
interact
visual
analog
scale
diva
mm
glasgow
pain
form
evalu
owner
blind
treatment
singl
veterinari
neurologist
blind
treatment
order
respect
present
day
statist
analysi
includ
mix
linear
model
follow
adjust
alpha
level
appropri
p
g
gm
decreas
pain
score
significantli
compar
present
placebo
use
cbpi
pain
mean
sd
g
placebo
present
g
gm
placebo
present
diva
mm
g
gm
placebo
present
gm
decreas
cbpi
function
significantli
compar
present
gm
placebo
present
cbpi
overal
impress
significantli
better
g
g
gm
placebo
present
csom
significantli
lower
treatment
includ
placebo
present
g
gm
placebo
present
base
owner
veterinarian
assess
gabapentin
alon
meloxicam
provid
pain
relief
neuropath
pain
human
glioma
appear
exploit
immun
inhibitori
pathway
maintain
immunosuppress
microenviron
bind
program
cell
death
protein
ligand
promot
activ
exhaust
tumor
cell
tc
evad
host
immun
attack
express
stimul
express
lymphocyt
til
accumul
intratumor
regulatori
treg
also
result
effector
inhibit
decreas
respons
littl
known
whether
canin
glioma
share
immunomodul
mechan
analyz
immunohistochem
express
retrospect
seri
canin
glioma
tissu
section
glioma
type
grade
immunostain
tumor
addit
stain
accumul
til
within
tumor
pronounc
astrocyt
oligodendrogli
tumor
mean
express
greater
glioma
signific
differ
oligodendroglioma
glioblastoma
p
tumor
contain
cell
mean
express
increas
grade
consider
higher
astrocyt
tumor
til
observ
case
howev
three
tumor
high
express
til
densiti
consid
posit
correl
express
r
p
first
studi
immunohistochem
character
treg
express
axi
canin
glioma
demonstr
spontan
canin
glioma
model
immun
evas
human
counterpart
support
use
canin
glioma
translat
immunotherapeut
studi
diagnosi
degen
myelopathi
dm
limit
lack
lesion
visibl
convent
mri
altern
diagnost
techniqu
need
diffus
tensor
imag
dti
advanc
mri
method
highli
sensit
detect
white
matter
lesion
hypothes
dti
measur
fraction
anisotropi
fa
would
alter
spinal
cord
dog
white
matter
lesion
caus
dm
twelv
dog
clinic
dm
eight
subsequ
histopatholog
confirm
healthi
control
hc
dog
neurolog
grade
anesthet
scan
mri
obtain
dti
data
whole
spinal
cord
data
mean
fa
document
spinal
cord
cervic
thorac
lumbar
site
data
assess
normal
distribut
thorac
data
highli
variabl
distribut
due
artefact
exclud
dunnett
perform
detect
differ
hc
mildli
affect
sever
affect
dm
cohort
statist
signific
differ
identifi
hc
sever
dm
cohort
mean
sd
hc
sever
p
hc
sever
p
trend
toward
signific
identifi
hc
sever
p
studi
identifi
although
statist
signific
alter
fa
present
spinal
cord
dog
sever
dm
method
diagnosi
may
insensit
detect
milder
lesion
earlier
stage
diseas
canin
degen
myelopathi
dm
progress
neurodegen
diseas
similar
human
amyotroph
later
sclerosi
al
tempor
dm
dog
central
nervou
system
cn
tissu
studi
demonstr
neuron
degener
astrogliosi
mid
lower
thorac
spinal
cord
among
locat
recent
identifi
transit
superoxid
dismutas
gene
predict
missens
mutat
underli
case
canin
dm
similarli
rodent
mous
rat
mutant
known
al
model
relat
cn
patholog
manifest
hallmark
cn
tissu
within
al
patient
dm
dog
mutant
rodent
loss
time
vs
healthi
control
diseas
speci
depend
excitatori
amino
acid
transport
protein
found
cn
astrocyt
glial
cell
region
cn
excitotox
injuri
promot
elev
neurotransmitt
concentr
thought
result
alter
activ
andor
astrocyt
avail
recent
new
positron
emiss
tomographi
pet
imag
radiolabel
tracer
known
target
cn
protein
synthes
purpos
studi
initi
evalu
whether
chang
male
femal
dm
dog
rel
healthi
control
detect
util
spinal
pet
imag
coupl
magnet
reson
mr
comput
tomographi
ct
anatom
tissu
data
anim
studi
adher
iacuc
approv
protocol
util
facil
aaalac
accredit
recruit
dog
reliant
pet
owner
particip
cohort
includ
healthi
control
hc
recent
diagnos
dm
dog
routin
autom
product
pet
tracer
perform
homogen
mbq
mci
dose
formul
ethanol
salin
ml
intraven
cathet
place
saphen
vein
dog
anesthet
place
within
imag
cradl
enabl
mr
scan
toshibacanon
mr
scanner
cervic
thorac
spine
region
cradl
dog
transport
scanner
wide
bore
toshibacanon
celesteion
purevis
tof
inject
tracer
intraven
dynam
pet
scan
cervic
thorac
region
min
perform
attenu
correct
ct
scan
dog
data
collect
differ
day
reconstruct
pet
data
frame
data
amid
softwar
spinal
cord
region
interest
cervic
thorac
defin
base
landmark
atlas
region
radioact
curv
time
determin
standard
uptak
valu
suv
similarli
suv
profil
heart
establish
defin
imag
deriv
tracer
input
function
use
tracer
kinet
model
paramet
afford
region
spinal
tracer
distribut
volum
vt
estim
follow
result
obtain
signal
cohort
includ
hc
age
rang
year
male
labrador
retriev
femal
beagl
x
chines
crest
bcc
dog
chesapeak
bay
retriev
cbr
boxer
bx
dm
recent
diagnos
age
rang
year
male
cbr
bx
pembrok
welsh
corgi
pwc
femal
bx
cbr
pwc
multipl
tracer
dose
afford
per
product
run
high
molar
activ
tbqmmol
puriti
imag
deriv
input
function
use
heart
left
ventricl
vt
estim
deriv
two
compart
one
tissu
kinet
model
signific
statist
differ
tracer
vt
found
thorac
spine
dm
cohort
lower
vt
valu
hc
cohort
anova
p
signific
vt
chang
cervic
spine
hc
vs
recent
diagnos
dm
found
conclud
hc
vs
recent
diagnos
dm
cohort
find
demonstr
pet
imag
sensit
detect
thorac
spinal
cord
protein
target
chang
initi
outcom
consist
previou
dm
spinal
patholog
determin
ex
vivo
measur
report
literatur
eg
ogawa
et
al
vet
path
therefor
impetu
advanc
longitudin
pet
imag
studi
dog
affect
dm
order
assess
progress
chang
variou
cn
tissu
purpos
two
part
studi
evalu
disposit
singl
extend
releas
levetiracetam
xrl
healthi
dog
bodi
weight
kg
part
time
serum
sampl
perform
dog
follow
administr
singl
mg
xrl
tablet
median
rang
cmax
tmax
auc
hour
h
ngml
respect
clinic
advers
effect
note
base
data
hour
dose
interv
chosen
studi
part
eight
dog
receiv
mg
xrl
tablet
q
h
day
time
serum
sampl
perform
day
trough
hour
tablet
administr
observ
individu
variat
neither
median
cmax
p
auc
p
significantli
differ
across
sampl
day
use
friedman
test
individu
chang
cmax
rang
median
decreas
serum
levetiracetam
concentr
day
day
median
individu
serum
levetiracetam
concentr
remain
minimum
human
therapeut
interv
point
evalu
clinic
advers
effect
report
dog
conclus
mg
xrl
given
twice
daili
day
result
serum
concentr
clinic
advers
effect
small
cohort
furthermor
signific
differ
serum
levetiracetam
concentr
note
sampl
day
current
dog
lose
deep
pain
percept
hindquart
follow
acut
thoracolumbar
intervertebr
disc
herniat
chanc
recov
abil
walk
pelvic
limb
month
investig
laboratori
rodent
human
patient
suggest
extens
durotomi
duroplasti
may
improv
outcom
acut
spinal
cord
contus
pilot
studi
consecut
dog
present
deep
pain
neg
paraplegia
follow
acut
intervertebr
disc
herniat
underw
continu
extend
durotomi
vertebr
length
cranial
caudal
lesion
epicent
immedi
follow
convent
decompress
surgeri
delay
onset
paraplegia
present
rang
minut
day
median
hour
nine
dog
definit
recov
walk
voluntarili
within
mean
day
five
dog
definit
recov
within
month
includ
one
develop
progress
myelomalacia
day
euthanat
one
recov
pain
sensat
could
walk
month
irrevoc
lost
within
month
includ
one
euthanat
day
chang
statu
median
delay
till
present
similar
dog
hour
hour
recov
four
dog
yet
complet
period
strongli
conclus
result
dog
know
outcom
appear
promis
prospect
random
trial
compar
outcom
convent
surgeri
vs
convent
surgeri
plu
extend
durotomi
necessari
defin
valu
intervent
similar
human
inflammatori
myopathi
im
canin
im
larg
group
disord
character
infiltr
inflammatori
cell
muscl
common
im
human
includ
polymyos
pm
dermatomyos
inclus
bodi
myositi
dog
im
masticatori
myositi
pm
myositi
caus
infecti
diseas
usual
protozo
infect
common
specif
aim
studi
character
im
small
famili
young
dutch
shepherd
dog
progress
clinic
sign
gener
muscl
weak
muscl
atrophi
persist
elev
serum
creatin
kinas
activ
physic
neurolog
examin
support
neuromuscular
diseas
affect
relat
dog
given
earli
onset
muscl
weak
presenc
relat
affect
dog
underli
genet
caus
suspect
histopatholog
skelet
muscl
biopsi
confirm
inflammatori
myopathi
infecti
possibl
dystroph
disord
consid
immunofluoresc
stain
use
phenotyp
cellular
infiltr
determin
major
histocompat
antigen
mhc
ii
overexpress
local
dystrophi
associ
protein
dysferlin
associ
strategi
use
map
chromosom
locu
follow
whole
genom
sequenc
wg
identifi
homozyg
substitut
gene
encod
mitochondri
transport
isoform
promin
express
brain
muscl
heart
skelet
muscl
transport
studi
perform
function
reconstitut
recombin
mutant
liposom
confirm
dramat
decreas
transport
activ
mutant
carrier
demonstr
pathogen
variant
addit
target
metabolom
analysi
skelet
muscl
affect
dog
control
demonstr
proinflammatori
milieu
strong
experiment
support
oxid
stress
affect
dog
muscl
first
descript
variant
associ
im
speci
first
report
underli
mutat
result
metabol
defect
associ
im
date
human
inherit
diseas
associ
mitochondri
transport
famili
report
result
pure
metabol
disord
includ
defect
mitochondri
energi
product
well
character
biochem
genet
defect
report
diseas
human
predominantli
associ
central
nervou
system
includ
development
delay
congenit
epilepsi
hypomyelin
possibl
autism
explan
muscl
primarili
affect
dog
variant
subject
futur
investig
mast
cell
tumor
mct
common
skin
malign
dog
pose
treatment
challeng
sever
reason
one
current
approv
therapeut
mct
us
develop
addit
treatment
option
import
advanc
clinic
manag
tigilanol
tiglat
isol
australian
rainforest
plant
fontainea
picrosperma
possess
antitumor
activ
stimul
enhanc
wound
heal
treatment
site
via
activ
protein
kinas
c
tigilanol
tiglat
may
effect
inject
intratumor
treatment
canin
cutan
subcutan
mct
one
hundr
dog
cutan
lower
limb
subcutan
mct
confirm
fine
needl
aspir
cytolog
enrol
studi
dog
random
treatment
singl
intratumor
inject
tigilanol
tiglat
sham
treatment
untreat
control
multicent
studi
primari
efficaci
outcom
complet
respons
cr
disappear
target
lesion
day
outcom
measur
includ
wound
heal
toler
safeti
hrqol
treat
dog
less
cr
could
receiv
second
intratumor
inject
tigilanol
tiglat
day
untreat
dog
could
cross
treatment
tigilanol
tiglat
day
one
hundr
eighteen
dog
evalu
sixti
dog
random
treatment
tigilanol
tiglat
achiev
cr
singl
intratumor
inject
compar
untreat
dog
day
p
eighteen
treat
dog
achiev
cr
receiv
second
intratumor
inject
percent
evalu
treat
dog
achiev
cr
within
possibl
treatment
strategi
percent
evalu
dog
achiev
cr
first
inject
remain
day
dog
random
untreat
control
group
cross
intratumor
tigilanol
tiglat
evalu
achiev
cr
day
remain
day
wound
develop
dog
treat
tigilanol
tiglat
heal
rapidli
day
wound
develop
anticip
patholog
associ
mechan
action
drug
frequent
advers
event
transient
reaction
treatment
site
owner
indic
overal
hrqol
treat
dog
similar
untreat
dog
tigilanol
tiglat
highli
effect
treatment
cutan
lower
limb
subcutan
mct
dog
well
toler
manag
side
effect
tigilanol
tiglat
potenti
play
import
role
expand
treatment
option
avail
dog
mct
primari
care
specialti
set
chemotherapi
cyclophosphamid
doxorubicin
vincristin
prednison
standard
care
canin
lymphoma
decad
purpos
studi
investig
whether
chop
combin
rate
radiat
therapi
ldrhbi
might
lead
improv
outcom
dog
diseas
juli
februari
vca
western
veterinari
specialist
centr
calgari
canada
offer
dog
lymphoma
potenti
superior
therapi
chop
alon
standard
stage
diagnost
perform
case
includ
screen
bloodwork
urinalysi
thorac
abdomin
imag
bone
marrow
aspir
cytolog
incision
lymph
node
biopsi
protocol
incorpor
use
ldrhbi
insert
week
cranial
half
caudal
half
cgi
deliv
use
low
dose
rate
extend
treatment
distanc
protocol
deliv
approxim
monitor
unitsminut
treatment
delay
chemotherapi
drug
dose
reduct
choic
concomit
medic
made
discret
attend
medic
oncologist
gem
ncss
v
statist
softwar
use
statist
analys
dog
enter
studi
intent
treat
basi
median
first
remiss
durat
group
dog
day
confid
interv
day
median
overal
surviv
time
reach
dog
lost
follow
dog
die
caus
still
first
remiss
median
day
rang
day
dog
still
aliv
first
remiss
median
day
rang
day
dog
experienc
gener
manag
toxic
includ
anorexia
dog
vomit
dog
diarrhea
dog
dog
develop
neutropenia
thrombocytopenia
receiv
antibiot
therapi
neutropenia
result
treatment
delay
dog
dose
reduct
made
last
resort
dog
lengthi
neutropenia
prompt
discontinu
therapi
dog
end
plan
protocol
mild
elev
blood
urea
nitrogen
andor
serum
creatinin
seen
dog
caudal
ldrhbi
two
dog
euthan
toxic
result
suggest
owner
dog
b
cell
lymphoma
will
accept
increas
cost
toxic
result
prolong
remiss
surviv
time
studi
human
determin
supraphysiolog
concentr
ascorb
plasma
concentr
mm
pharmacolog
ascorb
readili
produc
high
flux
via
oxid
preferenti
induc
cancer
cell
death
compar
normal
cell
vast
major
vitro
studi
focus
effect
human
tumor
cell
effect
canin
osteosarcoma
high
level
ascorb
achiev
dog
unknown
purpos
studi
determin
pharmacokinet
pk
profil
intraven
ascorb
healthi
beagl
dog
determin
effect
canin
osteosarcoma
cell
eight
beagl
dog
administ
two
dose
ascorb
mglb
mglb
via
intraven
infus
six
hour
separ
day
plasma
ascorb
concentr
measur
time
point
infus
pk
analysi
minor
advers
effect
seen
two
dog
mild
nausea
vomit
plasma
ascorb
level
peak
mm
follow
higher
dose
return
baselin
hour
dose
clonogen
assay
perform
canin
osteosarcoma
cell
line
normal
canin
fibroblast
cell
line
exposur
high
concentr
ascorb
ascorb
significantli
decreas
surviv
osteosarcoma
cell
spare
normal
fibroblast
data
indic
preferenti
cytotox
cancer
cell
high
level
ascorb
safe
administ
dog
studi
need
determin
effect
canin
cancer
patient
muscl
loss
common
diseas
age
difficult
quantit
assess
clinic
therefor
quantit
method
need
object
studi
evalu
ultrasound
techniqu
previous
valid
healthi
cat
dog
forelimb
epaxi
muscl
score
flem
well
muscl
condit
score
mc
cat
rang
healthi
muscl
mass
vari
degre
cachexia
sarcopenia
prospect
studi
cat
variou
age
bodi
condit
score
bc
mc
conduct
mean
epaxi
muscl
height
calcul
three
transvers
ultrasound
imag
obtain
thorac
vertebra
use
linear
transduc
ratio
epaxi
muscl
height
forelimb
circumfer
forelimb
epaxi
muscl
score
flem
calcul
compar
bodi
weight
mc
bodi
weight
bc
quantit
magnet
reson
qmr
measur
forelimb
circumfer
muscl
ultrasonograph
measur
assess
cat
msc
cat
assess
separ
time
separ
rater
mean
bodi
weight
kg
mean
bc
muscl
condit
score
normal
cat
cat
muscl
loss
mild
n
moder
n
sever
n
mean
epaxi
muscl
height
cm
mean
flem
significantli
correl
bodi
weight
epaxi
muscl
height
r
p
p
mc
r
p
p
p
significantli
correl
percent
lean
tissu
measur
qmr
prospect
studi
mc
flem
assess
muscl
mass
cat
warrant
pneumocysti
rare
opportunist
fungal
diseas
occur
anim
immun
compromis
recent
encount
young
miniatur
schnauzer
pneumocysti
pneumonia
predispos
risk
factor
identifi
dog
hypothes
primari
immunodefici
purpos
studi
determin
underli
genet
variant
preval
dog
without
pneumocysti
whole
genom
sequenc
affect
dog
perform
variant
call
use
standard
bioinformat
pipelin
filter
base
popul
frequenc
databas
dog
genom
variant
effect
role
gene
immun
function
variant
allel
frequenc
determin
three
dog
pneumocysti
shih
tzu
greyhound
cavali
king
charl
spaniel
bank
dna
miniatur
schnauzer
without
pneumocysti
put
causal
mutat
domin
splice
variant
potent
cytokin
provid
protect
immun
numer
infecti
pathogen
variant
absent
genom
databas
dog
three
pneumocysti
case
six
bank
miniatur
schnauzer
sampl
heterozyg
mutat
allel
frequenc
two
heterozygot
recurr
urinari
tract
infect
other
histori
infecti
diseas
mutat
discov
miniatur
schnauzer
pneumocysti
pneumonia
mutat
incomplet
penetr
could
due
genet
factor
environment
exposur
genet
immunodefici
like
exist
schnauzer
dog
pneumocysti
felin
upper
respiratori
infect
uri
import
infecti
diseas
complex
affect
felin
popul
particularli
popul
shelter
rescu
facil
clinic
sign
includ
conjunct
corneal
ulcer
ocular
discharg
well
typic
upper
respiratori
tract
sign
sneez
felin
uri
associ
number
pathogen
includ
felin
felin
caliciviru
fcv
pneumoviru
chlamydophila
feli
mycoplasma
sp
bordetella
bronchiseptica
streptococcu
equi
subsp
zooepidemicu
role
felin
coronaviru
fcov
primari
caus
agent
felin
uri
entir
clear
collect
swab
conjunctiva
nasal
caviti
cat
diagnos
felin
infecti
periton
fip
well
conjunctiva
nasal
ororphang
tissu
healthi
cat
cat
experienc
clinic
sign
associ
uri
fcov
detect
conjunctiv
nasal
oropharyg
region
cat
display
differ
degre
respiratori
sign
detect
within
fip
cat
upon
necropsi
nasal
turbin
fip
cat
examin
histolog
multifoc
region
pyogranulomat
inflamm
use
immunohistochemistri
fcov
antigen
detect
within
macrophag
area
inflamm
observ
support
respiratori
tract
infect
due
fcov
suggest
fcov
may
caus
felin
uri
canin
influenza
viru
civ
first
identifi
canada
end
found
dog
ontario
dec
oct
four
separ
cluster
identifi
associ
import
dog
asia
transmiss
identifi
within
kennel
dog
walk
oper
groomer
shelter
veterinari
clinic
high
attack
rate
common
expos
group
board
kennel
multipl
gener
transmiss
track
respons
identif
civ
includ
contact
trace
test
contact
serial
test
infect
dog
voluntari
quarantin
infect
dog
voluntari
closur
affect
kennel
groomer
restrict
admiss
one
veterinari
clinic
mandatori
confin
order
infect
dog
issu
public
health
part
one
cluster
civ
contain
cluster
appar
erad
largest
cluster
erad
april
civ
identifi
canada
octob
anoth
cluster
associ
import
dog
asia
cluster
erad
quickli
civ
diagnos
made
novemb
time
write
partial
h
sequenc
perform
subset
sampl
singl
sampl
test
cluster
ident
sampl
cluster
ident
ident
cluster
three
sampl
cluster
ident
cluster
appar
genet
drift
ident
within
household
subsequ
transmiss
strain
cluster
distinct
three
death
attribut
civ
infect
occur
diagnos
case
older
dog
underli
diseas
civ
also
suspect
least
one
addit
death
civ
introduc
repeatedli
immunolog
popul
howev
contain
measur
appar
effect
demonstr
potenti
valu
prompt
diagnosi
implement
civ
control
measur
allopurinol
increasingli
use
treatment
canin
viscer
leishmaniasi
cvl
format
urinari
xanthin
urolithiasi
relat
possibl
complic
allopurinol
therapi
aim
studi
evalu
incid
urolithiasi
dog
natur
infect
l
infantum
dog
natur
infect
l
infantum
includ
studi
survey
conduct
retrospect
evalu
medic
record
laboratori
test
januari
juli
inclus
criteria
dog
studi
either
posit
elisa
rifi
posit
reaction
snap
leishmania
idexx
medic
record
contain
complet
anamnesi
detail
type
feed
medic
administ
complementari
exam
abdomin
ultrasound
routin
urin
analysi
dog
nt
develop
advers
urinari
effect
develop
xanthin
urolithiasi
renal
miner
struvit
urolithiasi
calcium
oxal
urolithiasi
bilirubin
crystal
anim
develop
calcium
oxal
urolithiasi
vitamin
c
includ
daili
medic
dog
use
studi
use
vitamin
c
daili
prescript
suspens
allopurinol
dog
xanthin
urolithiasi
renal
miner
impli
improv
ultrasonograph
imag
month
xanthin
commonli
crystal
found
urin
dog
possibl
caus
continu
use
allopurinol
treatment
cvl
dog
receiv
therapi
monitor
begin
treatment
inform
regard
efficaci
angiotensin
ii
receptor
blocker
telmisartan
treatment
proteinuria
dog
limit
object
prospect
random
clinic
trial
evalu
antiproteinur
efficaci
oral
administ
telmisartan
dog
persist
patholog
renal
proteinuria
compar
enalapril
dog
chronic
kidney
diseas
urinari
ratio
upc
azotem
elig
enrol
dog
accord
presenc
absenc
azotemia
system
arteri
hypertens
receiv
telmisartan
mgkg
po
morn
equal
volum
placebo
daili
even
enalapril
mgkg
po
twice
daili
day
percentag
decreas
upc
day
compar
baselin
calcul
data
present
median
rang
total
dog
includ
baselin
systol
blood
pressur
serum
creatinin
concentr
upc
mmhg
mgdl
mmhg
mgdl
dog
respect
day
percentag
decreas
upc
significantli
greater
vs
dog
p
significantli
greater
proport
dog
compar
dog
experienc
reduct
upc
day
vs
respect
p
treatment
telmisartan
result
significantli
greater
decreas
upc
proteinur
dog
compar
enalapril
canin
hypoadrenocortic
ha
condit
pose
diagnost
challeng
especi
term
identifi
case
definit
test
studi
aim
valid
machin
learn
algorithm
mla
screen
test
cha
creat
graphic
user
interfac
gui
mla
easili
implement
clinic
complet
blood
count
cbc
serum
chemistri
sc
collect
retrospect
control
suspect
ha
diseas
rule
confirm
base
acth
stimul
test
ha
case
boost
tree
machin
learn
algorithm
mla
train
collect
data
util
test
perform
mla
learn
demonstr
mla
train
set
increas
dog
mla
sensit
ci
specif
ci
overal
accuraci
greater
nak
ratio
total
lymphocyt
count
logist
regress
combin
nak
lymphocyt
count
subset
ha
control
randomli
select
data
set
correspond
cbc
sc
data
assess
veterinarian
blind
fashion
base
cbc
chemistri
data
veterinarian
correctli
classifi
case
vs
correctli
classifi
mla
conclus
mla
implement
automat
screen
test
report
laboratori
alert
clinician
need
test
ha
confirmatori
test
phosphoru
p
essenti
nutrient
present
pet
food
two
form
organ
matter
meat
bone
meal
inorgan
p
ip
salt
recent
studi
confirm
diet
high
ip
content
neg
impact
felin
renal
health
hypothes
calcium
factor
may
influenc
plasma
p
level
potenti
provid
insight
outcom
follow
long
term
exposur
healthi
neuter
cat
fed
singl
exposur
test
meal
daili
energi
requir
crossov
design
trial
last
week
diet
contain
kcal
p
sodium
tripolyphosph
stpp
calcium
phosphoru
ratio
ca
p
plasma
p
ioniz
calcium
ica
parathyroid
hormon
pth
measur
serial
via
cephal
cathet
studi
protocol
review
approv
waltham
anim
welfar
ethic
review
bodi
compar
diet
g
p
kcal
ca
p
increas
ca
p
reduc
peak
plasma
p
concentr
mmoll
v
mmoll
p
durat
peak
plasma
p
return
baselin
v
p
diet
g
p
kcal
increas
ca
p
prevent
peak
plasma
p
p
pth
follow
pattern
plasma
p
increas
dietari
ca
p
reduc
peak
durat
plasma
p
pth
elev
follow
meal
long
term
feed
trial
confirm
whether
measur
reduc
risk
advers
kidney
chang
current
pain
control
periop
set
difficult
due
need
frequent
inject
opioid
drug
dog
novel
oral
methadon
formul
contain
human
abusemisus
deterr
naltrexon
evalu
dog
undergo
ovariohysterectomi
ohe
dog
randomli
assign
one
three
treatment
methadon
mgkg
sc
posit
control
n
dog
methadon
mgkg
fluconazol
mgkg
naltrexon
mgkg
po
n
dog
methadon
mgkg
fluconazol
mgkg
naltrexon
mgkg
po
n
dog
inject
methadon
start
hr
prior
iv
cathet
placement
oral
methadon
start
hr
prior
iv
cathet
placement
acepromazin
mgkg
sc
administ
dog
hr
prior
cathet
placement
propofol
administ
iv
cathet
induc
anesthesia
maintain
isofluran
standard
ohe
perform
dog
monitor
postop
pain
use
valid
modifi
glasgow
composit
pain
scale
gcp
intraven
cathet
success
place
dog
propofol
induct
dose
gcp
score
significantli
differ
p
treatment
dog
requir
rescu
analgesia
gcp
common
advers
effect
periop
vomit
significantli
differ
treatment
conclus
novel
twice
daili
oral
opioid
formul
contain
deterr
human
abusemisus
effect
provid
preoper
sedat
acepromazin
effect
control
postop
pain
dog
undergo
ohe
purpos
studi
assess
effect
ad
naltrexon
deterr
human
abusemisus
novel
oral
methadonefluconazol
formul
dog
hypothes
would
statist
differ
central
opioid
effect
similar
methadon
exposur
would
occur
group
twelv
healthi
beagl
dog
equal
divid
two
group
parallel
studi
studi
iacuc
approv
use
fda
approv
drug
group
administ
fluconazol
mgkg
po
hour
prior
methadonefluconazol
administr
group
administ
combin
methadon
mgkg
fluconazol
mgkg
po
group
addit
receiv
naltrexon
mgkg
po
concurr
rectal
temperatur
monitor
marker
central
opioid
effect
blood
obtain
interv
determin
plasma
methadon
naltrexon
activ
metabolit
inact
metabolit
rectal
temperatur
previous
correl
analgesia
dog
decreas
baselin
group
hour
drug
administr
significantli
differ
p
group
similar
methadon
plasma
concentr
measur
group
measur
group
dog
measur
dog
group
confirm
naltrexon
administr
naltrexon
ngml
measur
dog
time
point
ngml
measur
dog
conclus
central
opioid
effect
occur
dog
oral
methadonefluconazol
effect
deterr
human
abusemisus
naltrexon
incorpor
express
varieti
tissu
includ
intestin
limit
oral
absorpt
therapeut
drug
mani
veterinari
drug
substrat
includ
anticanc
agent
vincristin
doxorubicin
antidiarrh
agent
loperamid
parasiticid
macrocycl
lacton
signific
influenc
drug
disposit
risk
sever
advers
drug
reaction
function
defect
human
pharmaceut
compani
routin
screen
candid
drug
determin
whether
substrat
transport
avail
similar
inform
canin
current
lack
laboratori
recent
develop
ex
vivo
canin
enteroid
system
accur
model
physiolog
molecular
featur
intestin
tissu
environ
aim
research
assess
whether
enteroid
could
serv
drug
test
assay
canin
intestin
transport
express
assess
use
qpcr
intestin
tissu
enteroid
healthi
control
hc
protein
lose
enteropathi
ple
dog
dog
infest
roundworm
rw
immunofluoresc
stain
canin
enteroid
transwel
cultur
system
perform
assess
local
receptor
function
assay
perform
use
fluoresc
dye
substrat
without
verapamil
inhibitor
function
quantit
fluoresc
microscopi
imagej
knockout
gene
code
resist
achiev
canin
enteroid
lipofectamin
transfect
plasmid
target
natur
occur
delet
mutat
present
colli
breed
transfect
effici
monitor
green
fluoresc
protein
gfp
express
control
plasmid
transfect
enteroid
use
compar
mean
lumin
intens
obtain
imagej
test
use
compar
mean
quantit
cycl
obtain
qpcr
p
consid
statist
signific
gene
express
significantli
differ
p
enteroid
epitheli
layer
origin
intestin
tissu
quantit
cycl
valu
express
mean
sd
organoid
ple
rw
hc
tissu
ple
rw
hc
result
confirm
enteroid
express
compar
amount
report
vivo
cultur
primari
canin
enteroid
transwel
system
show
apic
express
consist
vivo
observ
verapamil
significantli
reduc
fluoresc
lumen
enteroid
approxim
seen
incub
alon
p
indic
transport
function
success
block
addit
canin
enteroid
success
transfect
stabl
manner
plasmid
knockout
summari
gene
express
local
function
canin
enteroid
similar
intestin
tissu
origin
deriv
knockout
express
canin
enteroid
mimic
dysfunct
present
certain
dog
breed
contribut
advers
drug
reaction
conclud
novel
enteroid
model
serv
use
ex
vivo
system
pharmaceut
drug
transport
safeti
studi
veterinari
medicin
chronic
musculoskelet
disord
csmd
affect
estim
million
cat
us
medic
approv
indic
nonsteroid
drug
nsaid
mainstay
treatment
musculoskelet
pain
inflamm
speci
hypothes
nsaid
robenacoxib
would
increas
physic
activ
improv
mobil
pain
qualiti
life
tempera
happi
cat
cmsd
otherwis
healthi
cat
n
cmsd
impair
enrol
blind
clinic
trial
cat
receiv
placebo
p
baselin
period
random
receiv
placebo
p
robenacoxib
r
two
consecut
treatment
period
treatment
group
ppp
prr
prp
activ
subject
owner
data
collect
data
analyz
use
gener
linear
model
follow
three
week
treatment
robenacoxib
compar
placebo
result
increas
overal
activ
p
increas
activ
p
increas
activ
p
improv
persist
six
week
analysi
percentag
cat
higher
activ
receiv
robenacoxib
receiv
placebo
count
p
count
p
activ
p
robenacoxib
treatment
associ
decreas
disabl
significantli
placebo
p
follow
six
week
treatment
signific
improv
tempera
p
happi
p
robenacoxib
advers
effect
occur
similar
frequenc
group
p
data
demonstr
robenacoxib
efficaci
treatment
cmsd
cat
object
evalu
short
intermedi
outcom
follow
multimod
medic
manag
alon
canin
tracheal
collaps
syndrom
ctc
design
retrospect
case
seri
anim
dog
materi
method
medic
record
ctc
dog
prescrib
multimod
medic
regimen
includ
patient
receiv
endolumin
stent
extralumin
ring
prosthes
exclud
analysi
medic
record
review
pertin
patient
data
clinic
score
surviv
outcom
clinic
score
divid
mild
moder
sever
categori
result
total
medic
manag
dog
ctc
includ
follow
median
day
rang
day
studi
popul
dog
tracheal
collaps
ttc
dog
tracheal
collaps
mtc
dog
ctc
indetermin
type
last
examin
phone
amc
visit
worsen
clinic
sign
honkingraspi
breath
cough
dyspnea
clinic
score
report
dog
despit
medic
manag
respect
median
surviv
time
mst
day
rang
day
older
dog
year
old
shorter
mst
day
compar
younger
dog
p
dog
sever
clinic
score
least
one
categori
last
examin
mst
day
conclus
clinic
relev
multimod
medic
manag
ctc
alon
absenc
endolumin
surgic
treatment
associ
median
surviv
time
year
popul
dog
chronic
enteropathi
cat
mostli
compris
inflammatori
bowel
diseas
ibd
small
cell
lymphoma
scl
differenti
remain
challeng
despit
variou
diagnost
measur
use
histopatholog
immunohistochemistri
clonal
test
parr
histolog
guid
mass
spectrometri
hgm
technolog
allow
analysi
endogen
molecul
directli
paraffin
embed
ffpe
tissu
section
assist
histopatholog
annot
target
analysi
cell
subpopul
hgm
use
gener
situ
molecular
fingerprint
ffpe
tissu
section
cat
ibd
n
scl
n
case
classifi
either
ibd
scl
base
histopatholog
indic
addit
immunohistochemistri
clonal
test
ffpe
tissu
section
deparaffin
underw
antigen
retriev
subject
tryptic
digest
mass
spectra
collect
histopatholog
preselect
area
monomorph
pleomorph
lymphocyt
popul
target
region
linear
discrimin
analysi
classif
algorithm
creat
use
acquir
mass
spectral
data
result
accuraci
perform
intern
cross
valid
assess
total
peak
use
build
model
found
statist
signific
two
group
appli
bonferroni
correct
two
signific
peak
within
mass
spectra
underw
analysi
use
tandem
mass
spectrometri
tent
identifi
beta
actin
histon
express
beta
actin
higher
cat
ibd
histon
express
higher
cat
scl
result
indic
mass
spectrometri
may
power
tool
accur
differenti
felin
scl
ibd
studi
current
progress
valid
result
use
independ
larger
cohort
sampl
ursodeoxychol
acid
ursodiol
natur
occur
bile
acid
use
treat
varieti
hepat
gastrointestin
diseas
ursodiol
multitud
benefici
therapeut
effect
modul
bile
acid
pool
bile
acid
alter
gut
microbiota
commun
structur
variou
mechan
turn
gut
microbi
commun
modul
bile
acid
pool
thu
highlight
interconnected
gut
axi
despit
interact
remain
unclear
exogen
administ
ursodiol
shape
indigen
gut
microbi
commun
structur
intestin
bile
acid
metabolom
studi
aim
provid
comprehens
analysi
ursodiol
alter
intestin
ecosystem
convent
mice
wildtyp
mice
oral
gavag
one
three
dose
ursodiol
mgkgday
repres
respect
day
alter
gut
microbiota
bile
acid
pool
examin
rrna
gene
illumina
sequenc
target
bile
acid
metabolom
stool
ileal
cecal
content
bile
acid
also
measur
serum
alter
microbi
commun
structur
seen
ileal
cecal
content
compar
baselin
longitudin
fece
follow
ursodiol
treatment
specif
ileal
content
microbi
commun
structur
treatment
significantli
differ
baselin
cecal
content
microbi
commun
structur
treatment
significantli
differ
baselin
ileal
cecal
content
member
lachnospiracea
famili
significantli
contribut
alter
observ
use
random
forest
analysi
signific
increas
serum
tauroursodeoxychol
acid
tudca
ursodeoxychol
acid
udca
lithochol
acid
lca
identifi
mice
treat
ursodiol
dose
depend
manner
ileal
content
udca
tudca
significantli
increas
dose
depend
manner
cecal
content
tudca
tcdca
significantli
increas
conclus
ursodiol
administr
convent
mice
result
signific
alter
indigen
gut
microbi
commun
structur
bile
acid
metabolom
studi
first
provid
comprehens
profil
exogen
administ
ursodiol
shape
intestin
ecosystem
studi
investig
chang
turn
modifi
host
physiolog
respons
ongo
veterinari
medicin
ursodiol
routin
administ
howev
ramif
drug
impact
canin
felin
intestin
ecosystem
unknown
addit
studi
elucid
ursodiol
modifi
gut
axi
speci
necessari
initi
step
pathway
oxid
tryptophan
kynurenin
express
increas
gastrointestin
tract
human
inflammatori
bowel
diseas
ibd
due
proinflammatori
cytokin
activ
receptor
increas
express
associ
lower
serum
tryptophan
concentr
human
ibd
due
increas
tryptophan
catabol
dog
enteropathi
ple
decreas
serum
tryptophan
concentr
compar
appar
healthi
dog
howev
express
previous
assess
intestin
mucosa
dog
ple
therefor
studi
aim
determin
signific
differ
mrna
express
duoden
mucosa
dog
ple
compar
healthi
dog
whether
express
correl
serum
tryptophan
concentr
dog
ple
studi
retrospect
studi
use
archiv
duoden
biopsi
dog
diagnos
ple
bristol
veterinari
school
previous
serum
tryptophan
concentr
measur
part
separ
studi
healthi
beagl
dog
iowa
state
univers
servic
coloni
novel
rna
situ
hybrid
ish
technolog
rnascop
use
hybrid
mrna
probe
onto
least
duoden
biopsi
tissu
section
dog
rnascop
signal
visual
use
microscop
singl
oper
perform
quantit
assess
dog
ple
significantli
higher
mrna
express
duoden
mucosa
compar
healthi
control
beagl
dog
averag
copi
per
cell
p
mean
ple
control
ii
averag
area
per
cell
p
ple
control
iii
percentag
posit
p
ple
control
iv
p
ple
control
mrna
express
duoden
mucosa
neg
correl
serum
tryptophan
concentr
dog
ple
averag
copi
per
cell
spearman
rank
correl
coeffici
srcc
p
ii
averag
area
per
cell
srcc
p
iii
percentag
posit
srcc
p
iv
srcc
p
studi
suggest
decreas
serum
tryptophan
concentr
dog
ple
might
due
increas
intestin
express
studi
need
determin
inflammatori
pathway
respons
increas
express
intestin
tract
dog
ple
